REGENXBIO Inc. (RGNX) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome everyone to the Regenexx BIO RGX 202 Topline Pivotal Data Webcast. At this time, I'd like to turn the conference over to Patrick Christmas, Chief Legal Officer of Regenexx BIO. Please go ahead. Good morning, and thank you for joining us today. Earlier this morning, Regenexx Bio released pivotal, top-line data from the Affinity Duchenne trial of RGX202, as well as financial and operating results for the first quarter ended March 31, 2026. The press releases are available on our website at www.regenexxbio.com. Today's webcast will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted and can be identified by words such as expect, plan, will, may, anticipate, believe, should, intend, and other words of similar meaning. Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties. These risks are described in the risk factors and the management's discussion and analysis sections of Regenexx Bio's annual report on Form 10-K for the full year ended December 31st, 2025, and comparable risk factor sections of Regenexx Bio's quarterly reports on Form 10-Q, which are on file with the Securities and Exchange Commission and available on the SEC's website. Any information we provide on this conference call is provided only as of the date of this call, May 14th, 2026, and we undertake no obligation to update any forward-looking statements we may make on this call on account of new information, future events, or otherwise. Please be advised that today's call is being recorded and webcast. In addition, any unaudited...